These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 21215696)

  • 1. Clopidogrel Resistance: case reports of CYP2C19 gene variants in suspected coronary stent thrombosis.
    Dick RJ; Dear AE; Byron KA
    Heart Lung Circ; 2011 Oct; 20(10):657-8. PubMed ID: 21215696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement.
    Hochholzer W; Trenk D; Fromm MF; Valina CM; Stratz C; Bestehorn HP; Büttner HJ; Neumann FJ
    J Am Coll Cardiol; 2010 Jun; 55(22):2427-34. PubMed ID: 20510210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
    Sibbing D; Koch W; Gebhard D; Schuster T; Braun S; Stegherr J; Morath T; Schömig A; von Beckerath N; Kastrati A
    Circulation; 2010 Feb; 121(4):512-8. PubMed ID: 20083681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype.
    Kim IS; Jeong YH; Park Y; Park KS; Yun SE; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
    JACC Cardiovasc Interv; 2011 Apr; 4(4):381-91. PubMed ID: 21511217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.
    Gladding P; Webster M; Zeng I; Farrell H; Stewart J; Ruygrok P; Ormiston J; El-Jack S; Armstrong G; Kay P; Scott D; Gunes A; Dahl ML
    JACC Cardiovasc Interv; 2008 Dec; 1(6):620-7. PubMed ID: 19463375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomics of clopidogrel: evidence and perspectives.
    Yin T; Miyata T
    Thromb Res; 2011 Oct; 128(4):307-16. PubMed ID: 21592545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study.
    Gladding P; White H; Voss J; Ormiston J; Stewart J; Ruygrok P; Bvaldivia B; Baak R; White C; Webster M
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1095-101. PubMed ID: 19926050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients.
    Namazi S; Kojuri J; Khalili A; Azarpira N
    Biochem Pharmacol; 2012 Apr; 83(7):903-8. PubMed ID: 22265638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping.
    Alexopoulos D; Dimitropoulos G; Davlouros P; Xanthopoulou I; Kassimis G; Stavrou EF; Hahalis G; Athanassiadou A
    JACC Cardiovasc Interv; 2011 Apr; 4(4):403-10. PubMed ID: 21511219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2).
    Collet JP; Hulot JS; Anzaha G; Pena A; Chastre T; Caron C; Silvain J; Cayla G; Bellemain-Appaix A; Vignalou JB; Galier S; Barthélémy O; Beygui F; Gallois V; Montalescot G;
    JACC Cardiovasc Interv; 2011 Apr; 4(4):392-402. PubMed ID: 21511218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.
    Wei YQ; Wang DG; Yang H; Cao H
    PLoS One; 2015; 10(7):e0132561. PubMed ID: 26147597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
    Sibbing D; Koch W; Massberg S; Byrne RA; Mehilli J; Schulz S; Mayer K; Bernlochner I; Schömig A; Kastrati A
    Eur Heart J; 2011 Jul; 32(13):1605-13. PubMed ID: 21527445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome p-450 polymorphisms and response to clopidogrel.
    Mega JL; Close SL; Wiviott SD; Shen L; Hockett RD; Brandt JT; Walker JR; Antman EM; Macias W; Braunwald E; Sabatine MS
    N Engl J Med; 2009 Jan; 360(4):354-62. PubMed ID: 19106084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome.
    Wang XQ; Shen CL; Wang BN; Huang XH; Hu ZL; Li J
    Gene; 2015 Mar; 558(2):200-7. PubMed ID: 25542807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel].
    Cano P; Consuegra-Sánchez L; Conesa P; Torres-Moreno D; Jaulent L; Dau D; Picó F; Villegas M
    Med Clin (Barc); 2014 Jul; 143(1):6-12. PubMed ID: 23850044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of genetic factors to stent thrombosis due to clopidogrel resistance after coronary stent placement.
    Kirac D; Erdem A; Avcilar T; Yesilcimen K; Guney AI; Emre A; Yazici S; Terzi S; Kaspar EC; Cetin SE; Isbir T
    Cell Mol Biol (Noisy-le-grand); 2016 Jan; 62(1):51-5. PubMed ID: 26828987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2C19 genotype-guided antiplatelet therapy in a patient with clopidogrel resistance.
    Rai M; Seip RL; Gupta A; McKay RG; Hirst J; Thompson PD; Ruaño G
    Conn Med; 2012 May; 76(5):267-72. PubMed ID: 22685981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
    Collet JP; Hulot JS; Pena A; Villard E; Esteve JB; Silvain J; Payot L; Brugier D; Cayla G; Beygui F; Bensimon G; Funck-Brentano C; Montalescot G
    Lancet; 2009 Jan; 373(9660):309-17. PubMed ID: 19108880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects.
    Mao L; Jian C; Changzhi L; Dan H; Suihua H; Wenyi T; Wei W
    Arch Cardiovasc Dis; 2013 Oct; 106(10):517-27. PubMed ID: 24080325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel low responders undergoing coronary stenting for non ST elevation acute coronary syndrome.
    Cuisset T; Quilici J; Cohen W; Fourcade L; Saut N; Pankert M; Gaborit B; Carrieri P; Morange PE; Bonnet JL; Alessi MC
    Am J Cardiol; 2011 Sep; 108(6):760-5. PubMed ID: 21803320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.